StockData
Amgen Inc logo

Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen kANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Rest of World (ROW) product sales ($M) ($M)

Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail

QuarterlyAnnual
Latest, Q4 2023
11
Period ended Dec 31, 2023
Change on a year earlier
-15.4%
13 in Q4 2022
History
20 quarters
Since Q1 2019
Sources
20
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Rest of World (ROW) product sales ($M) ($M)Year on yearSource
Q4 2023Dec 31, 202311-15.4%Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 202313-7.1%Form 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 202312-25.0%Form 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 202314-12.5%Form 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 202213-7.1%Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 202214-41.7%Form 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗
Q2 2022Jun 30, 202216-33.3%Form 8-K (amgn-2022630earningsrelease.htm, filed 2022-08-04) ↗
Q1 2022Mar 31, 202216-48.4%Form 8-K (amgenq12022earningsrelease.htm, filed 2022-04-27) ↗
Q4 2021Dec 31, 202114-51.7%Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗
Q3 2021Sep 30, 202124+33.3%Form 8-K (amgn-2021930xq3ex991.htm, filed 2021-11-02) ↗
Q2 2021Jun 30, 202124+9.1%Form 8-K (amgn-2021630xq2ex991.htm, filed 2021-08-03) ↗
Q1 2021Mar 31, 202131+34.8%Form 8-K (amgn-2021331xq1ex991.htm, filed 2021-04-27) ↗
Q4 2020Dec 31, 202029+20.8%Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗
Q3 2020Sep 30, 202018-40.0%Form 8-K (amgn-2020930xq3ex991.htm, filed 2020-10-28) ↗
Q2 2020Jun 30, 202022-26.7%Form 8-K (amgn-2020630xq1ex991.htm, filed 2020-07-28) ↗
Q1 2020Mar 31, 202023-4.2%Form 8-K (amgn-2020331xq1ex991.htm, filed 2020-04-30) ↗

Cite this data

StockData. (2026). Amgen KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Rest of World (ROW) product sales ($M) ($M), quarterly Q1 2019–Q4 2023 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_kanjinti_row

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.